Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Equity: 2021-2025

Historic Return on Equity for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to -0.48%.

  • SAB Biotherapeutics' Return on Equity rose 62.00% to -0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.48%, marking a year-over-year increase of 62.00%. This contributed to the annual value of -1.01% for FY2024, which is 5.00% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Return on Equity stood at -0.48% for Q3 2025, which was up 80.33% from -2.44% recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Return on Equity high stood at -0.44% for Q1 2022, and its period low was -2.44% during Q2 2025.
  • Its 3-year average for Return on Equity is -1.20%, with a median of -1.10% in 2024.
  • Within the past 5 years, the most significant YoY rise in SAB Biotherapeutics' Return on Equity was 62bps (2025), while the steepest drop was 163bps (2025).
  • SAB Biotherapeutics' Return on Equity (Quarterly) stood at -0.47% in 2021, then fell by 14bps to -0.61% in 2022, then slumped by 56bps to -1.16% in 2023, then grew by 12bps to -1.04% in 2024, then spiked by 62bps to -0.48% in 2025.
  • Its last three reported values are -0.48% in Q3 2025, -2.44% for Q2 2025, and -1.62% during Q1 2025.